Common Stock, par value $0.01 per share
- Symbol
- MNKD
- Exchange
- NASDAQ
- Classification
- COMMON
- Status
- Current
Current Report · Items 2.02, 9.01 · 8-K
MannKind Corporation
MNKDNASDAQEQUITYCurrent
Results of Operations and Financial Condition
Item 2.02. Results of Operations and Financial Condition. On August 5, 2026, MannKind Corporation issued a press release, a copy of which is furnished herewith as Exhibit 99.1 and is incorporated herein by reference.
Press release in this filing
Achieved three major catalysts to drive future growth →Company context
MannKind Corporation (Nasdaq: MNKD) is a biopharmaceutical company dedicated to transforming chronic disease care through innovative, patient-centric solutions. Focused on cardiometabolic and orphan lung diseases, we develop and commercialize treatments that address serious unmet medical needs, including diabetes, pulmonary hypertension, and fluid overload in heart failure and chronic kidney disease.
Current securities
Historical securities (1)
Registered securities in this filing
MannKind Corporation · 8-K · Filed 2026-08-05
Disclosure sections
Item 2.02Item 2.02 - Results of Operations
Item 2.02. Results of Operations and Financial Condition.
On August 5, 2026, MannKind Corporation issued a press release, a copy of which is furnished herewith as Exhibit 99.1 and is incorporated herein by reference.
Filed exhibits (1)
EX-99.1 2 mnkd-ex99_1.htm EX-99.1 EX-99.1 MannKind Reports Second Quarter 2026 Financial Results and Provides Business Update • Achieved three major catalysts to drive future growth: o Launched the pediatric indication of Afrezza® following FDA approval o FUROSCIX ReadyFlow™ autoinjector approved for treatment of edema in HF and CKD o Positive nintedanib DPI Phase 1b data in IPF patients validates continued Phase 2 advancement • Encouraging early momentum in Afrezza pediatric launch o 1 in 3 of the top 100 pediatric insulin writers have prescribed • Q2 2026 total revenues of $109.4M, +43% vs. Q2 2025 • Conference call and webcast today at 4:30 p.m. ET DANBURY, Conn. and WESTLAKE VILLAGE, Calif., August 5, 2026 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) a biopharmaceutical company dedicated to transforming chronic disease care through innovative, patient-centric solutions for cardiometabolic and orphan lung diseases, today reported financial results for the second quarter of 2026, and provided a business update. “This was a transformative period for MannKind, during which we delivered all three major catalysts we set out to achieve in 2026,” said Mic…
Open exhibit ↗